This week in drug discovery (18-22 November)
News round-up for 18-22 November by DDW Senior Digital Content Editor Diana Spencer.
This week’s most exciting news stories all represent innovative solutions to the treatment of disease, proving that ‘thinking outside the box’ can by the key to success in drug discovery.
The top stories:
Preclinical data supports T cell engager in autoimmune disease
Positive preclinical data for novel CD19xCD3 T cell engager CLN-978 have supported its potential as a new therapeutic option for autoimmune diseases.
Hydrogel enhances antibiotics’ effect against resistant bacteria
New research has shown that resistant bacteria can regain susceptibility to antibiotics when the treatment is combined with a material equipped with antibacterial peptides.
Whole-genome sequencing reveals new potential cancer-driving genes
Researchers have identified 330 potential cancer-driving genes, 74 of which are newly associated with cancer.
£1 million PACE grant to accelerate precision antibiotics
Glox Therapeutics has secured £1 million in grant funding from Pathways to Antimicrobial Clinical Efficacy (PACE), one of the UK’s largest public-private initiatives targeting early-stage antimicrobial medicines and diagnostic discovery.
Highly promising new oral approach to abdominal pain
University of Queensland (UQ) researchers have developed a new class of oral painkillers to suppress chronic abdominal pain that is based on the peptide hormone oxytocin.
